John Orloff, M.D., has been appointed vice president and global head of R&D for Baxter BioScience. Dr. Orloff will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model and pursuing additional opportunities for the business.
Dr. Orloff joins the company from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Previously, he spent 10 years at Novartis, where he served various roles of increasing responsibility, including chief medical officer for global development. Dr. Orloff also supported clinical development at Merck Research Labs. Dr. Orloff brings expertise in bone biology, and has led programs across a range of therapeutic areas, including immunology, neurology and oncology.
“As we work toward becoming an independent global biopharmaceutical company, our priorities are to drive innovation by advancing our rich, late-stage development pipeline, expanding our expertise in immunology, hematology, and other core technologies and optimizing our R&D productivity,” said Ludwig Hantson, Ph.D., president of Baxter BioScience. “John brings significant scientific and leadership expertise, including preclinical research, clinical development, and medical and regulatory affairs. He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organization.”